Meng Zhaoting, Chen Peng, Zang Fenglin, Liu Ying, Xu Xiaoyan, Su Yudong, Chen Jinliang, Lin Li, Zhang Lu, Zhang Tengfei
Department of Thoracic Medical Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin.
Burning Rock Biotech, Guangzhou, China.
Onco Targets Ther. 2017 Dec 28;11:157-161. doi: 10.2147/OTT.S150001. eCollection 2018.
Pulmonary blastoma (PB) is a rare aggressive lung malignancy with a poor prognosis. Surgical resection is the treatment of choice for localized disease, and there are no standard treatment guidelines for metastatic PB. Due to its rareness, its molecular profile has not been elucidated. We present the first case of classic biphasic pulmonary blastoma (CBPB) with rearrangement in a 44-year-old Asian female with stage IV disease diagnosed using capture-based ultra-deep targeted sequencing. It has been reported that rearranged lung adenocarcinoma and squamous cell carcinoma are sensitive to crizotinib, an multitargeted tyrosine kinase inhibitor. However, its efficacy has not been reported in CBPB patients harboring rearrangement. This CBPB patient was given crizotinib and she achieved partial response after 1 month of treatment. We report the first clinical evidence of efficacy shown by crizotinib for targeting fusion in CBPB.
肺母细胞瘤（PB）是一种罕见的侵袭性肺恶性肿瘤，预后较差。手术切除是局限性疾病的首选治疗方法，而转移性PB尚无标准治疗指南。由于其罕见性，其分子特征尚未阐明。我们报告了首例经典双相肺母细胞瘤（CBPB），该病例为一名44岁的亚洲女性，患有IV期疾病，通过基于捕获的超深度靶向测序诊断出存在[此处原文缺失具体基因重排内容]重排。据报道，[此处原文缺失具体基因重排内容]重排的肺腺癌和鳞状细胞癌对克唑替尼敏感，克唑替尼是一种多靶点酪氨酸激酶抑制剂。然而，其在携带[此处原文缺失具体基因重排内容]重排的CBPB患者中的疗效尚未见报道。该CBPB患者接受了克唑替尼治疗，治疗1个月后获得部分缓解。我们报告了克唑替尼针对CBPB中[此处原文缺失具体基因重排内容]融合显示疗效的首个临床证据。
